Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Halobetasol propionate (BMY-30056) 是一种在皮肤外使用的合成类固醇,具有抗炎,止痒和收缩血管的活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 279 | 现货 | ||
25 mg | ¥ 453 | 现货 | ||
50 mg | ¥ 641 | 现货 | ||
100 mg | ¥ 969 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 250 | 现货 |
产品描述 | Halobetasol propionate (BMY-30056) is the propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, this agent induces phospholipase A2 inhibitory proteins, which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. As a result, halobetasol reduces edema, erythema, and pruritus through its cutaneous effects on vascular dilation and permeability. |
体外活性 | Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.[1] |
别名 | 卤贝他索丙酸酯, Halobetasol Propionate, Ulobetasol propionate, BMY-30056, 卤倍他索丙酸酯, CGP-14458 |
分子量 | 484.96 |
分子式 | C25H31ClF2O5 |
CAS No. | 66852-54-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 36 mg/mL (74.2 mM)
DMSO: 90 mg/mL (185.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.062 mL | 10.3101 mL | 20.6203 mL | 51.5506 mL |
5 mM | 0.4124 mL | 2.062 mL | 4.1241 mL | 10.3101 mL | |
10 mM | 0.2062 mL | 1.031 mL | 2.062 mL | 5.1551 mL | |
20 mM | 0.1031 mL | 0.5155 mL | 1.031 mL | 2.5775 mL | |
50 mM | 0.0412 mL | 0.2062 mL | 0.4124 mL | 1.031 mL | |
DMSO | 100 mM | 0.0206 mL | 0.1031 mL | 0.2062 mL | 0.5155 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Halobetasol propionate 66852-54-8 Metabolism Phospholipase 卤贝他索丙酸酯 Inhibitor BMY30056 BMY 30056 Ulobetasol Propionate Halobetasol Propionate Halobetasol (propionate) CGP14458 inhibit Ulobetasol propionate CGP 14458 BMY-30056 卤倍他索丙酸酯 CGP-14458 inhibitor